Alere Inc (ALR)

50.42
NYSE : Health Care
Prev Close 50.42
Day Low/High 0.00 / 0.00
52 Wk Low/High 31.47 / 50.55
Avg Volume 1.71M
Exchange NYSE
Shares Outstanding 87.37M
Market Cap 4.41B
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Abbott CEO Miles White said on an earnings call the company will make one more asset sale as part of efforts to gain regulatory approval for the Abbott-Alere deal.

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Abbott will report second-quarter numbers on Thursday as it completes the Alere deal. $ABT $ALR

Alere Launches Alere ICup® Rx Drug Screen For Detecting Commonly Misused And Abused Prescription Drugs

Alere Launches Alere ICup® Rx Drug Screen For Detecting Commonly Misused And Abused Prescription Drugs

Rapid Urine Test Facilitates Real-time Monitoring of Use, Misuse and Abuse of Clinically Relevant Prescription Pain and Addiction Therapies

Quidel Diversifies With Alere's Triage Assets

Quidel Diversifies With Alere's Triage Assets

The Triage assets are being divested in order to secure antitrust approvals for Abbott Laboratories' purchase of Alere.

Earnings Previews: 7 Names to Report This Week

What we'll be looking for from ABT, NUE, DHR, KEY, SNA, GE and SLB.

Short Interest In Alere Moves 17.3% Higher

Short Interest In Alere Moves 17.3% Higher

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 496,718 share increase in total short interest for Alere Inc. , to 3,374,652, an increase of 17.26% since 06/15/2017.

Weekly Roundup

Jobs report and Fed minutes highlight a short week. In the portfolio, we add one name and downgrade another.

Alere Shareholders Vote to Approve Amended Merger with Abbott

Alere Shareholders Vote to Approve Amended Merger with Abbott

The final vote results will be filed on a Form 8-K with the Securities and Exchange Commission.

Weekly Roundup

Tech rotation, oil and Fed rate hike keep markets on even (make that flat) keel. Several portfolio positions get beefed up.

Abbott Is on Track to Meet Integration Objectives

In turn, this will increase the company's profit margins.

Weekly Roundup

After a busy Thursday, markets look forward to economic data and the Fed meeting next week. In the portfolio, we dropped a tech stock and added a healthcare name.

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Greenlight Capital Quadrupled General Motors Stake in Activist Push

Greenlight Capital Quadrupled General Motors Stake in Activist Push

David Einhorn is going all-in on General Motors.

Alere Launches The Alere™ Malaria Ag P.f, The First-Ever Rapid Test To Screen Malaria Infection In Asymptomatic Individuals

New test provides powerful tool to help meet malaria eradication goals

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.

Alere Stock Surging on Latest Abbott Agreement

Alere Stock Surging on Latest Abbott Agreement

Abbott will now pay a lower price to acquire Alere.

Can Abbott Outperform Despite Alere?

Can Abbott Outperform Despite Alere?

Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.